Sunosi (Solriamfetol HCl) Patent Expiration, LOE Window & CMS Spending
Sunosi (Solriamfetol HCl) by Axsome Malta: FDA Orange Book core substance LOE 2038-11-01 (last listed 2042-12-30), 3 AB generics, $33.9M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Axsome Malta |
| FDA Application & Pathway | N211230 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-11-01 |
| Last Listed Patent or Exclusivity Date | 2042-12-30 |
| Orange Book Patents (*PED Extensions) | 42 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $33.9M |
| 2024 Medicare Part D Spend | $21.0M |
| 2024 Medicaid Spend | $12.9M |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 24.7% 2-yr change) |